His July speech at the Bitcoin Conference, in Nashville, was a turning point for crypto, promising an easier path for the industry heading into 2025.
ZachXBT: Master Sleuth of Crypto
Nobody catches blockchain criminals better.
Matthew Long: The UK’s Crypto Gatekeeper
Under Long, the Financial Conduct Authority has been slow to approve crypto firms operating in the UK. Impending new rules may change that, however.
Microsoft Shareholders Vote Down Bitcoin Treasury Proposal
The negative vote was expected even as MicroStrategy Executive Chairman Michael Saylor tried to convince Microsoft shareholders otherwise.
Google stock pops as company unveils new quantum computing chip
Google said that a math equation that would take a classical supercomputer longer than the whole history of the universe to solve takes only five minutes using a quantum computer powered by its new Willow chip.
C3.ai Stock Volatile as CEO Puts Some Shares for Sale, Offsetting Strong Results
A regulatory filing showed C3.ai founder and CEO Thomas Siebel was selling 12.78 million shares of the artificial intelligence software company
Russian Lawmaker Proposes Creating Strategic Bitcoin Reserve: Report
Anton Tkachev proposed "assessing the feasibility of creating a strategic BTC reserve in Russia by analogy with state reserve in traditional currencies."
What's Going On With Eli Lilly Stock On Tuesday?
On Monday, Eli Lilly And Co (NYSE:LLY) announced results from the Phase 3 BRUIN CLL-321 trial evaluating pirtobrutinib in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) previously treated with a covalent BTK inhibitor. The study’s primary endpoint of progression-free survival (PFS) was met at primary analysis, demonstrating pirtobrutinib was superior to the investigator’s choice of idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR). A
HealthEquity Stock Falls on Disappointing Outlook
HealthEquity shares fell Tuesday after the company's full-year profit and sales outlook missed analysts' estimates.
CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets
On Tuesday, CervoMed Inc. (NASDAQ:CRVO) stock is trading lower after the company revealed topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for dementia with Lewy bodies (DLB). The trial did not meet statistical significance thresholds for its primary endpoint of change in the Clinical Dementia Rating Sum of Boxes (a measure of dementia severity) or any of its key secondary endpoints – change from baseline in Timed Up and Go (measures a person’s mobility, balance, a